. 2015 Oct 20;18(2):184–190. doi: 10.1093/europace/euv294

Table 4.

Difference between adjusted means of rivaroxaban and vitamin K antagonist therapy by the cardioversion strategy (intention-to-treat population)

Subscale^a	Cardioversion strategy	Adjusted mean	95% confidence interval	P-value
Convenience	Early	11.26	7.32 to 15.20	<0.001
Convenience	Delayed	15.96	12.35 to 19.57	<0.001
Effectiveness	Early	2.31	−0.14 to 4.76	0.064
Effectiveness	Delayed	6.46	3.93 to 8.99	<0.001
Global satisfaction	Early	13.10	9.34 to 16.87	<0.001
Global satisfaction	Delayed	15.33	11.62 to 19.04	<0.001
Side-effects	Early	4.10	−0.62 to 8.82	0.089
Side-effects	Delayed	2.55	−2.64 to 7.74	0.333

^aScore scales range from 0 to 100; adjusted means, means adjusted by the cardioversion strategy. If questions 4–6 were ticked as ‘not applicable’, this was recorded as ‘missing’.